Holding(s) in Company

RNS Number : 2868Q

Allergy Therapeutics PLC

07 April 2009

 



For filings with the FSA include the annex For filings with issuer exclude the annex

TR-1: Notifications of Major Interests in Shares

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Allergy Therapeutics Plc

2. Reason for notification (yes/no)
An acquisition or disposal of voting rights	X
An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An event changing the breakdown of voting rights
Other (please specify):______________

3. Full name of person(s) subject to notification obligation:	FIL Limited (FIL)
4. Full name of shareholder(s) (if different from 3):	See attached schedule
5. Date of transaction (and date on which the threshold is crossed or reached if different):	06 April 2009
6. Date on which issuer notified:	07 April 2009
7. Threshold(s) that is/are crossed or reached:	11%

8: Notified Details
A: Voting rights attached to shares
Class/type of shares If possible use ISIN code	Situation previous to the triggering transaction		Resulting situation after the triggering transaction
	Number of shares	Number of voting rights	Number of shares	Number of voting rights		Percentage of voting rights
				Direct	Indirect	Direct	Indirect
ISIN GB00B02LCQ05	9,033,043	9,033,043	8,854,410	8,854,410		10.80

B: Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument	Expiration date	Exercise/ conversion period/date	No. of voting rights that may be acquired (if the instrument exercised/converted)	Percentage of voting rights

Total (A+B)
Number of voting rights	Percentage of voting rights
8,854,410	10.80

9. Chain of controlled undertakings through which the voting rights and /or the financial instruments are effectively held, if applicable:

See attached schedule

Proxy Voting:
10. Name of proxy holder:	FIL Limited (FIL)
11. Number of voting rights proxy holder will cease to hold:	178,633
12. Date on which proxy holder will cease to hold voting rights:	06 April 2009

13. Additional information:	None
14 Contact name:	Amanda Chana
15. Contact :	[e-mail]

FIL

 

Issuer Name:                                              ALLERGY THERAPEUTICS LTD

 

Current ownership percentage:                          10.80%

Total Shares Held:                                       8,854,410

Issued Share Capital:                                  81,950,632

 

 

SHARES HELD	NOMINEE	MANAGEMENT COMPANY
105,467	JPMORGAN, BOURNEMOUTH	FIL
8,748,943	JPMORGAN, BOURNEMOUTH	FISL

 

FIL Limited (FIL) is the parent holding company for various direct and indirect subsidiaries, including FIL Fund Management Limited (FFML), FIL Investment Services Ltd (FISL), FIL Gestion (FIGEST), FIL Asset Management (Korea) Limited (FIAKL), FIL Investments Management (Hong Kong) Limited (FIMHK), FIL Pension Management (FPM), Fidelity Investments Japan (FIJ) and FIL Investments International (FII), Investment managers for various non-US investment companies and institutional clients.

For notes on how to complete form TR-1 please see the FSA website. 

 

END

 

 

HOLUBRORKRRSRAR